Candel Therapeutics CEO Paul FMedSci's 2022 pay jumps 93% to $1.8M
Candel Therapeutics reports 2022 executive compensation
By ExecPay News
Published: May 23, 2023
Candel Therapeutics reported fiscal year 2022 executive compensation information on May 23, 2023.
In 2022, three executives at Candel Therapeutics received on average a compensation package of $1.2M, a 113% increase compared to previous year.
Average pay of disclosed executives at Candel Therapeutics
Paul Peter Tak, M.D., Ph.D., FMedSci, Chief Executive Officer, received $1.8M in total, which increased by 93% compared to 2021. 36% of FMedSci's compensation, or $670K, was in salary. FMedSci also received $260K in non-equity incentive plan, $351K in option awards, $335K in stock awards, as well as $229K in other compensation.
Seshu Tyagarajan, Ph.D., RAC, Chief Technical and Development Officer, received a compensation package of $916K. 50% of the compensation package, or $455K, was in option awards.
Francesca Barone, Chief Scientific Officer, earned $908K in 2022, a 149% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on May 23, 2023.